Income Statement Acorda Therapeutics OTC Markets
Stocks
ACOR
US00484M7002
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-10.00% | -99.91% |
| 24-08-13 | First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. | CI |
| 24-08-07 | Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc. | CI |
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 192M | 153M | 129M | 119M | 118M | |||||
Total Revenues | 192M | 153M | 129M | 119M | 118M | |||||
Cost of Goods Sold, Total | 34.85M | 56.18M | 50.61M | 36.14M | 20.44M | |||||
Gross Profit | 158M | 96.78M | 78.46M | 82.43M | 97.2M | |||||
Selling General & Admin Expenses, Total | 190M | 153M | 119M | 106M | 89.7M | |||||
R&D Expenses | 58.68M | - | - | - | - | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 25.64M | 30.76M | 30.76M | 30.76M | 30.76M | |||||
Other Operating Expenses | - | - | - | -12.55M | - | |||||
Other Operating Expenses, Total | 274M | 183M | 150M | 124M | 120M | |||||
Operating Income | -117M | -86.55M | -71.3M | -41.78M | -23.26M | |||||
Interest Expense, Total | -21.87M | -30.57M | -30.04M | -30.2M | -31.53M | |||||
Interest And Investment Income | 4.17M | 816K | 5K | 1.91M | 530K | |||||
Net Interest Expenses | -17.7M | -29.76M | -30.03M | -28.29M | -31M | |||||
Currency Exchange Gains (Loss) | - | - | - | -8K | -288K | |||||
Other Non Operating Income (Expenses) | 13K | 40.13M | 1.15M | 1.29M | 51K | |||||
EBT, Excl. Unusual Items | -134M | -76.19M | -100M | -68.8M | -54.5M | |||||
Restructuring Charges | -4.4M | -343K | -6M | -251K | - | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | -278M | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | -57.9M | - | - | 171K | |||||
Asset Writedown | - | -4.13M | - | - | -251M | |||||
In Process R&D Expenses | - | - | - | - | - | |||||
Other Unusual Items | 142M | 30.89M | -2.9M | 33.8M | 9.63M | |||||
EBT, Incl. Unusual Items | -274M | -108M | -109M | -35.25M | -296M | |||||
Income Tax Expense | -1.28M | -8.07M | -5.12M | 30.67M | -43.17M | |||||
Earnings From Continuing Operations | -273M | -99.59M | -104M | -65.92M | -253M | |||||
Net Income to Company | -273M | -99.59M | -104M | -65.92M | -253M | |||||
Minority Interest | - | - | - | - | - | |||||
Net Income - (IS) | -273M | -99.59M | -104M | -65.92M | -253M | |||||
Net Income to Common Incl Extra Items | -273M | -99.59M | -104M | -65.92M | -253M | |||||
Net Income to Common Excl. Extra Items | -273M | -99.59M | -104M | -65.92M | -253M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -689.42 | -246.4 | -195.75 | -66.9 | -203.59 | |||||
Basic EPS - Continuing Operations | -689.42 | -246.4 | -195.75 | -66.9 | -203.59 | |||||
Basic Weighted Average Shares Outstanding | 396K | 404K | 531K | 985K | 1.24M | |||||
Net EPS - Diluted | -690 | -246.4 | -195.8 | -66.9 | -203.59 | |||||
Diluted EPS - Continuing Operations | -690 | -246.4 | -195.8 | -66.9 | -203.59 | |||||
Diluted Weighted Average Shares Outstanding | 396K | 404K | 531K | 985K | 1.24M | |||||
Normalized Basic EPS | -211.99 | -117.8 | -117.9 | -43.64 | -27.43 | |||||
Normalized Diluted EPS | -211.99 | -117.8 | -117.9 | -43.64 | -27.43 | |||||
Supplemental Items | ||||||||||
EBITDA | -82.63M | -45.66M | -37.65M | -9.08M | 8.4M | |||||
EBITA | -90.97M | -55.79M | -40.54M | -11.02M | 7.5M | |||||
EBIT | -117M | -86.55M | -71.3M | -41.78M | -23.26M | |||||
EBITDAR | -69.56M | -33.3M | -26.61M | -3.22M | 10.38M | |||||
Total Revenues (As Reported) | 192M | 153M | 129M | 119M | 118M | |||||
Effective Tax Rate - (Ratio) | 0.47 | 7.5 | 4.69 | -87.01 | 14.58 | |||||
Current Domestic Taxes | 621K | -11.59M | -48K | 358K | 968K | |||||
Current Foreign Taxes | 75K | 65K | 113K | 37K | 71K | |||||
Total Current Taxes | 696K | -11.52M | 65K | 395K | 1.04M | |||||
Deferred Domestic Taxes | -1.98M | 4.37M | -5.12M | 30.27M | -44.21M | |||||
Deferred Foreign Taxes | - | -926K | -62K | - | - | |||||
Total Deferred Taxes | -1.98M | 3.45M | -5.18M | 30.27M | -44.21M | |||||
Normalized Net Income | -83.93M | -47.62M | -62.61M | -43M | -34.06M | |||||
Interest on Long-Term Debt | 21.87M | 30.57M | 30.04M | 30.2M | 31.53M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 60.08M | 23.01M | 10.42M | 5.8M | 5.15M | |||||
Net Rental Expense, Total | 13.07M | 12.36M | 11.04M | 5.86M | 1.97M | |||||
Imputed Operating Lease Interest Expense | 7.05M | 11M | 11.27M | 7.68M | 2.74M | |||||
Imputed Operating Lease Depreciation | 6.02M | 1.35M | -233K | -1.83M | -763K | |||||
Stock-Based Comp., COGS (Total) | 624K | 2.08M | 713K | 75K | 11K | |||||
Stock-Based Comp., R&D Exp. (Total) | 2.81M | - | - | - | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | 10.81M | 6.02M | 2.28M | 1.42M | 467K | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 14.25M | 8.1M | 3M | 1.5M | 478K |
- Stock Market
- Stocks
- ACOR.Q Stock
- ACOR Stock
- Financials Acorda Therapeutics
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















